用于纵向检测高危黑色素瘤患者分子残留疾病的定制ctDNA。

IF 7.1 2区 医学 Q1 ONCOLOGY
S. Genta , D.V. Araujo , K. Hueniken , C. Pipinikas , R. Ventura , P. Rojas , G. Jones , M.O. Butler , S.D. Saibil , C. Yu , A. Easson , A. Covelli , M.B. Sauder , C. Fournier , Z. Saeed Kamil , P. Rogalla , D.P. Arteaga , O. Vornicova , P. Spiliopoulou , T.P. Muniz , A. Spreafico
{"title":"用于纵向检测高危黑色素瘤患者分子残留疾病的定制ctDNA。","authors":"S. Genta ,&nbsp;D.V. Araujo ,&nbsp;K. Hueniken ,&nbsp;C. Pipinikas ,&nbsp;R. Ventura ,&nbsp;P. Rojas ,&nbsp;G. Jones ,&nbsp;M.O. Butler ,&nbsp;S.D. Saibil ,&nbsp;C. Yu ,&nbsp;A. Easson ,&nbsp;A. Covelli ,&nbsp;M.B. Sauder ,&nbsp;C. Fournier ,&nbsp;Z. Saeed Kamil ,&nbsp;P. Rogalla ,&nbsp;D.P. Arteaga ,&nbsp;O. Vornicova ,&nbsp;P. Spiliopoulou ,&nbsp;T.P. Muniz ,&nbsp;A. Spreafico","doi":"10.1016/j.esmoop.2024.103978","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.</div></div><div><h3>Patients and methods</h3><div>We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years.</div></div><div><h3>Results</h3><div>ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-surgical sample). Positive ctDNA at landmark was associated with shorter overall survival (OS; median OS 22.7 months versus not reached, log-rank <em>P</em> value = 0.01) and a trend towards a shorter relapse-free survival (RFS; median RFS 15.7 months versus not reached, log-rank <em>P</em> value = 0.07). In 10 patients, ctDNA detection preceded disease relapse by a median of 128 days (range 8-406 days).</div></div><div><h3>Conclusions</h3><div>Our data indicate that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 11","pages":"Article 103978"},"PeriodicalIF":7.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients\",\"authors\":\"S. Genta ,&nbsp;D.V. Araujo ,&nbsp;K. Hueniken ,&nbsp;C. Pipinikas ,&nbsp;R. Ventura ,&nbsp;P. Rojas ,&nbsp;G. Jones ,&nbsp;M.O. Butler ,&nbsp;S.D. Saibil ,&nbsp;C. Yu ,&nbsp;A. Easson ,&nbsp;A. Covelli ,&nbsp;M.B. Sauder ,&nbsp;C. Fournier ,&nbsp;Z. Saeed Kamil ,&nbsp;P. Rogalla ,&nbsp;D.P. Arteaga ,&nbsp;O. Vornicova ,&nbsp;P. Spiliopoulou ,&nbsp;T.P. Muniz ,&nbsp;A. Spreafico\",\"doi\":\"10.1016/j.esmoop.2024.103978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.</div></div><div><h3>Patients and methods</h3><div>We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years.</div></div><div><h3>Results</h3><div>ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-surgical sample). Positive ctDNA at landmark was associated with shorter overall survival (OS; median OS 22.7 months versus not reached, log-rank <em>P</em> value = 0.01) and a trend towards a shorter relapse-free survival (RFS; median RFS 15.7 months versus not reached, log-rank <em>P</em> value = 0.07). In 10 patients, ctDNA detection preceded disease relapse by a median of 128 days (range 8-406 days).</div></div><div><h3>Conclusions</h3><div>Our data indicate that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence.</div></div>\",\"PeriodicalId\":11877,\"journal\":{\"name\":\"ESMO Open\",\"volume\":\"9 11\",\"pages\":\"Article 103978\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2059702924017484\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Open","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2059702924017484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:局部晚期黑色素瘤的预后不一。目前,还没有可靠的标准来对疾病复发风险进行分层,并确定哪些患者将从辅助治疗中获益最多。循环肿瘤DNA(ctDNA)是一种新兴的生物标记物,可测量血液中是否存在肿瘤衍生DNA:我们使用一种定制的肿瘤信息测定法(RaDaR®,NeoGenomics 公司)检测了 276 份前瞻性采集的血浆样本中的ctDNA,这些样本来自 66 位接受明确治疗的黑色素瘤患者。结果:19 名患者(29%)的至少一份血浆样本中检测到了ctDNA,其中 6/65 (9%)在标志性时间(手术后样本)检测到了ctDNA。ctDNA阳性与较短的总生存期(OS;中位数OS为22.7个月,未达到OS,log-rank P值=0.01)和较短的无复发生存期(RFS;中位数RFS为15.7个月,未达到RFS,log-rank P值=0.07)相关。在10例患者中,ctDNA检测的中位时间比疾病复发早128天(范围为8-406天):我们的数据表明,术后检测ctDNA可以发现预后较差的患者,连续的ctDNA测量可以更早地发现疾病复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients

Background

Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most from adjuvant therapies. Circulating tumor DNA (ctDNA) is an emerging biomarker measuring the presence of tumor-derived DNA in blood.

Patients and methods

We used a bespoke, tumor-informed assay (RaDaR®, NeoGenomics, Inc.) to detect ctDNA in 276 prospectively collected plasma samples from 66 melanoma patients receiving definitive treatment. Collection time points included landmark (after completion of local treatment) and every 3-6 months for up to 2 years.

Results

ctDNA was detected in at least one plasma sample in 19 patients (29%), including 6/65 (9%) at landmark (post-surgical sample). Positive ctDNA at landmark was associated with shorter overall survival (OS; median OS 22.7 months versus not reached, log-rank P value = 0.01) and a trend towards a shorter relapse-free survival (RFS; median RFS 15.7 months versus not reached, log-rank P value = 0.07). In 10 patients, ctDNA detection preceded disease relapse by a median of 128 days (range 8-406 days).

Conclusions

Our data indicate that ctDNA detection after surgery can identify patients with worse prognosis, and serial ctDNA measurements may enable earlier identification of disease recurrence.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESMO Open
ESMO Open Medicine-Oncology
CiteScore
11.70
自引率
2.70%
发文量
255
审稿时长
10 weeks
期刊介绍: ESMO Open is the online-only, open access journal of the European Society for Medical Oncology (ESMO). It is a peer-reviewed publication dedicated to sharing high-quality medical research and educational materials from various fields of oncology. The journal specifically focuses on showcasing innovative clinical and translational cancer research. ESMO Open aims to publish a wide range of research articles covering all aspects of oncology, including experimental studies, translational research, diagnostic advancements, and therapeutic approaches. The content of the journal includes original research articles, insightful reviews, thought-provoking editorials, and correspondence. Moreover, the journal warmly welcomes the submission of phase I trials and meta-analyses. It also showcases reviews from significant ESMO conferences and meetings, as well as publishes important position statements on behalf of ESMO. Overall, ESMO Open offers a platform for scientists, clinicians, and researchers in the field of oncology to share their valuable insights and contribute to advancing the understanding and treatment of cancer. The journal serves as a source of up-to-date information and fosters collaboration within the oncology community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信